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Abstract
Introduction: Immune thrombocytopenic purpura is thought to be characterized by an immune response against
the host’s own platelets. If the thrombocytopenia is severe, patients are initially treated with high-dose steroids.
Other more toxic second line treatments are considered if steroids fail. Here, we report the case of two patients in
whom conventional treatment was unsuccessful but who responded to hydroxychloroquine and high-dose vitamin
D replacement therapy. To the best of our knowledge, this is the first description of successful treatment for
immune thrombocytopenia with high-dose vitamin D and hydroxychloroquine.
Case presentation: Case 1: We report the case of a 79-year-old Caucasian man who presented with high titer
antinuclear antibodies, positive anti-SSA/Ro autoantibodies and clinically was felt to have an overlap of systemic
lupus erythematosus and/or Sjögren’s syndrome with profound life-threatening thrombocytopenia. There was no
evidence of underlying malignancy. The patient’s platelet count significantly increased with vitamin D and
hydroxychloroquine treatment, but upon vitamin D discontinuation his platelet levels plummeted.
Hydroxychloroquine therapy was maintained throughout treatment. With reinstitution of high-dose vitamin D
therapy, platelet counts were restored to normal levels.
Case 2: We also report the case of an 87-year-old Caucasian woman who presented with high titer antinuclear
antibodies, positive anti-SSA/Ro autoantibodies and was felt to have an overlap of systemic lupus erythematosus
and/or Sjögren’s syndrome with immune thrombocytopenia; she also had severely low levels of 25-hydroxy vitamin
D (17ng/mL). There was no evidence of underlying malignancy. She responded to high-dose vitamin D
replacement and hydroxychloroquine treatment, thereby alleviating the need for high-dose steroid treatment. She
remains in remission while taking vitamin D, hydroxychloroquine and very low-dose prednisone. No untoward side
effects were observed in either patient.
Conclusions: In our two case reports, we found an association between vitamin D deficiency and immune
thrombocytopenia where platelet levels responded to vitamin D treatment and hydroxychloroquine but not to
prednisone. We believe there may be synergism between vitamin D supplementation and hydroxychloroquine. The
mechanism by which high-dose vitamin D results in increased platelet counts in immune thrombocytopenia
patients is unknown. However, vitamin D has long been thought to play an immunomodulatory role, which may
include a dampened immune response in patients with immune thrombocytopenia or other autoimmune diseases.
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Immune thrombocytopenic purpura (ITP) is thought to
be an autoimmune disorder mediated by autoantibodies
with no known etiology, and the incidence is approxi-
mately 2.5 per 100,000 persons per year [1]. The goal of
treatment is to keep the platelet count above 3×10
4/mm
3
to prevent major internal organ bleeding.
Current treatment involves intravenous corticosteroids,
immunosuppressants such as mycophenolate mofetil and
azathioprine, Cytoxan
W (cyclophosphamide), and intraven-
ous immunoglobulin (IVIg) [2]. Anti-D immunoglobulin
can only be given to RhD-positive individuals, thus limiting
treatment options for RhD-negative persons [3]. Rituximab,
a chimeric monoclonal antibody, has also been tried as an
experimental treatment [4], and combinations of therapies
have been used with some success [5]. Each of these
therapies may be associated with significant side effects and
efficacy is often temporary, requiring either additional and/
or alternative treatment. Many of the side effects of steroids
are well known and include hypertension, diabetes, osteo-
porosis and adrenal insufficiency. Several of these drugs are
carcinogenic and there have been reports of malignancy
formation after treatment, for example a high risk of acute
myelogenous leukemia after Cytoxan
W treatment [6].
Response rates vary, and there is currently no consensus
regarding the appropriate treatment protocol for this condi-
tion [7]. Corticosteroids show efficacy in 50% to 80% of
cases, but if treatment is stopped, the remission rate is only
10% to 30% [8]. If patients are refractory to drug treat-
ments, splenectomy is a second line option; two-thirds of
patients who undergo splenectomy for ITP respond to the
treatment [9]. However, complications may arise from this
surgical procedure including hemorrhage, abscess, sepsis,
thrombosis and death and relapse of ITP occurs in a
median of 15% of patients [9]. These patients are at lifelong
risk for infection from Streptococcus pneumoniae, Neisseria
meningitides and Haemophilus influenza [10].
Therefore, caution must be used in the treatment of ITP.
Aggressive treatment should be reserved for patients with
severe and symptomatic thrombocytopenia, and more
treatment options are needed to further guide disease
management. A successful treatment for any disease should
be non-toxic, inexpensive and easily administered. The
need for novel treatments for ITP is therefore imperative.
Here, we report two cases of patients with severe
ITP who responded to high-dose vitamin D and
Plaquenil
W (hydroxychloroquine) but who failed con-
ventional therapies.
Case presentation
Case 1
A 79-year-old Caucasian man was referred for manage-
ment of severe ITP. Serology was positive for both anti-
SSA/Ro autoantibodies (SSA) and antinuclear antibodies
(ANA) suggesting that the patient had an overlap of sys-
temic lupus erythematosus (SLE) and/or Sjögren’ss y n -
drome. In addition, he was cytopenic and complained of
dry eyes and mouth (sicca symptoms) and joint pain,
which are secondary symptoms of SLE and/or Sjögren’s
syndrome. The oncology clinic found no evidence of
an underlying malignancy responsible for this life-
threatening hematologic condition. The patient received
WinRho
W (IV Immune globulin, or IVIg) and high-dose
prednisone (60mg/day) after his platelet count had dropped
to 9000/mm
3 (normal >140,000/mm
3). Because the platelet
count only increased to 43,000/mm
3,t h eo n c o l o g i s tw a s
concerned that prednisone alone was not effective. The
patient was therefore referred to a rheumatology clinic for
other therapeutic options.
To treat the ITP, we administered Plaquenil
W
(hydroxychloroquine) 200mg twice a day, prednisone
15mg/day and high-dose vitamin D 50,000IU once a
week. The patient had a borderline low vitamin D level of
34ng/mL; in our experience with other autoimmune
diseases, we have found an enhanced therapeutic response
to standard treatment when a patient’s vitamin D level
increases to 40ng/mL to 50ng/mL or above.
The patient’s platelet count increased slightly to
55,000/mm
3 2 weeks after this treatment began. To
achieve an enhanced clinical benefit, vitamin D dosing
was increased to 150,000IU per week and prednisone was
lowered to 10mg/day; Plaquenil
W (hydroxychloroquine)
remained at 400mg/day.
His platelet count had increased to 114,000/mm
3 2
months after his initial visit. Prednisone was tapered to
5mg/day and vitamin D was lowered to 50,000IU twice a
week whereas Plaquenil
W (hydroxychloroquine) was not
altered.
The patient’s platelet count had increased to 141,000/
mm
3 3 months after the initial visit. Vitamin D was
maintained at 100,000IU per week, prednisone was
maintained at 5mg/day, and Plaquenil
W (hydroxychloro-
quine) remained at 400mg/day.
The patient’s platelet count remained stable for approxi-
mately 6 months on this regimen. When his platelet
counts stabilized (at 140,000/mm
3), high-dose vitamin D
supplementation was discontinued. He remained on
400mg/day Plaquenil
W (hydroxychloroquine) and predni-
sone (5mg/day).
The patient’s platelet count dropped to 18,000/mm
3 a
month after vitamin D supplementation was discontinued.
In response to this substantial decrease, the patient was
again prescribed vitamin D at 50,000IU twice a week and
prednisone 30mg/day; after 3 weeks, his platelet count
had increased to 91,000/mm
3.
A month later his platelet count increased to
137,000/mm
3 and prednisone was reduced to 5mg/day
(vitamin D and Plaquenil
W (hydroxychloroquine) treatment
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161,000/mm
3 4 months later. With the patient clinic-
ally stable, prednisone treatment was discontinued.
Vitamin D was reduced to 50,000IU once a week and
Plaquenil
W (hydroxychloroquine) was continued at the
same dose as before.
His platelet count was 215,000/mm
3 6 weeks after
discontinuing prednisone, indicating a regimen of
Plaquenil
W (hydroxychloroquine) 200mg twice a day and
vitamin D 50,000IU once a week alone was sufficient to
maintain a stable count. The patient remained stable off
prednisone.
Even with high-dose vitamin D, there were no signifi-
cant changes in calcium, phosphate, or creatinine levels.
Case 2
An 87-year-old Caucasian woman was referred to our
clinic from the oncology service with a platelet count of
8000/mm
3. She presented with an ANA at 1:640, positive
SSA, complained of dry eyes and dry mouth, and was
cytopenic. Her total complement was also elevated at 86
hemolytic units. The patient was felt to have an overlap
syndrome of SLE and Sjögren’s with an immune thrombo
cytopenia. Her initial 25-hydroxy (25-OH) vitamin D level
was 17ng/mL.
She was started on Plaquenil
W (hydroxychloroquine)
200mg twice a day and maintained on prednisone
40mg/day, which had been initiated by the hematology-
oncology service. Because of severely low levels of 25-OH
vitamin D, she was started on vitamin D 50,000IU
once a week.
A month later the patient was doing well and
vitamin D treatment was continued at 50,000IU once
a week. Because her platelet count had increased to
72,000/mm
3, her prednisone dose was tapered from
40mg to 15mg.
The patient’s platelet count had increased to 301,000/
mm
3 6 weeks after her initial visit and she was therefore
maintained on Plaquenil
W (hydroxychloroquine), vitamin
D (50,000IU once a week) and prednisone (tapered to
7.5mg).
Her platelet count dropped to 89,000/mm
3 6 weeks
later. Her vitamin D treatment at 50,000IU was increased
to twice weekly and prednisone and Plaquenil
W (hydroxy
chloroquine) were maintained at 7.5mg and 400mg,
respectively.
A month after starting the new high-dose vitamin D
regimen the patient was doing well; she had no
complaints and had a normal energy level. At this time,
her platelet count had increased to 244,000/mm
3 and
therefore prednisone was tapered to 5mg. The patient’s
vitamin D levels elevated to 89ng/mL. She continued
on Plaquenil
W (hydroxychloroquine; 400mg/day) and
vitamin D 50,000IU twice a week.
After 9 weeks on this dosage (Plaquenil
W (hydroxy
chloroquine) 400mg/day, vitamin D 100,000IU/week,
and prednisone 5mg/day), her platelet count was
176,000/mm
3, which increased to 212,000/mm
3 a month
later. At this time, the prednisone was decreased to
4mg/day and 6 weeks later her platelet count was
194,000/mm
3.
She continued on prednisone 4mg/day and Plaquenil
W
(hydroxychloroquine) 400mg/day, and received a lower
dose of vitamin D (50,000IU/week). After 16 weeks, her
platelet count remained high at 182,000/mm
3;p r e d n i s o n e
was decreased to 2 mg/day.
The patient remained in remission 2.5 years after her
initial presentation with a platelet count of 169,000/mm
3
on vitamin D 50,000IU/month, prednisone 2mg/day and
Plaquenil
W (hydroxychloroquine) 400mg/day.
She remains stable 4.5 years post-initial presentation
on a lower dose of Plaquenil
W (hydroxychloroquine;
200mg/day) that was started 6 months prior, prednisone
2mg/day and vitamin D 50,000IU/month.
Discussion
Immune thrombocytopenia is an autoimmune disease in
which platelets are targeted by the host immune system.
Platelet depletion occurs when autoantibodies targeting
glycoproteins found on the surface of platelets opsonize
the cells, resulting in destruction by macrophages. These
antibodies can also bind to megakaryocytes and prevent
complete maturation, which results in lowered levels of
platelet production [11,12]. Several treatments are cur-
rently in use in the clinical setting that increase platelet
counts, including steroid and immunosuppressive therapy.
Vitamin D, or 1,25-dihydroxyvitamin D3 (1,25(OH)
2D3), may be a potent immunomodulator, and it may
have potential therapeutic use in many autoimmune dis-
eases. In 1991, researchers found that the production of
interleukin (IL)-6 and IL-2 in cell cultures were reduced
by 1,25(OH)2D3 [13]. It was postulated that 1,25(OH)
2D3 may inhibit the production and function of IL-6
and, therefore, regulate lymphocyte functions. Activation
of the vitamin D receptors (VDRs) is known to alter
immune cell transcriptional patterns, proliferation and dif-
ferentiation through several intracellular pathways [14].
Both CD4+ and CD8+ lymphocytes contain significant
amounts of VDRs, and thus it is reasonable to conclude
that 1,25(OH)2D3 may play a role in the regulation of the
immune response [15].
It has been documented that patients with immune
thrombocytopenia have high rates of mononuclear cell
proliferation as well as lymphocytes that secrete greater
amounts of IL-2 compared to controls [16]. Researchers
have also shown that in these patients, depleting CD8+
lymphocytes and complement did not reduce proliferation
of mononuclear cells, which indicates that CD4+ T helper
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suggests that stimulated CD4+ T helper cells mediate
antibody production and maturation of B lymphocytes,
and may contribute to the eventual autoantibody response
targeting these patients’ platelets.
Several studies have shown that 1,25(OH)2D3 can inhibit
the development of multiple sclerosis in the murine model
[18,19]. Researchers suggest that CD4+ T cells may be the
target of 1,25(OH)2D3 immunosuppression and studies
have found that 1,25(OH)2D3 can inhibit T-cell pro-
liferation and activation. Other studies have shown
that vitamin D stimulates transforming growth factor
(TGF)-β1 and IL-4 production, which in turn may
suppress inflammatory T-cell activity [20,21]. TGF-β1
may help direct T-cell differentiation and promote the pro-
duction of T regulatory cells via the Foxp3 transcription
regulatory pathway resulting in the observed immunosup-
pression [22]. In fact, studies have shown that TGF-β1i s
able to promote T-cell differentiation from non-suppressor
CD4+ T cells simply through Foxp3 induction [23]. These
T regulatory cells help suppress the immune response and
thus maintain immune system homeostasis and tolerance
to self-antigens.
Although the number of T regulatory cells in ITP
patients is significantly reduced [17], recent research has
shown that it is possible to generate T regulatory cells
in vitro by pharmacologically manipulating the dendritic
cells with glucocorticoid and 1,25(OH)2D3 [24].
Drug-induced effects on dendritic cells included
induction of IL-10-secreting regulatory T cells, attenuation
of IL-2 and interferon gamma secretion, prevention of
T-cell IL-4 secretion, and suppression of antigen-
specific primary T-cell proliferation [14]. Overall, 1,25
(OH)2D3 seems to have two important immunomodula-
tory functions: down-regulation of over proliferative CD4+
cells and concurrent up-regulation of T regulatory
cells. Together, these effects may have the potential
to reduce the autoantibody response and may poten-
tially explain the restoration of platelet levels upon
treatment of high-dose vitamin D in patients who
have autoimmune thrombocytopenia.
Conclusions
In this case report, we describe an association between
vitamin D deficiency and immune thrombocytopenia in
two patients. Both patients had SLE and/or Sjögren’s
overlap with positive serology and profound life-
threatening thrombocytopenia, all of which were
unaffected by conventional therapies. High-dose replace-
ment of vitamin D plus the addition of Plaquenil
W
(hydroxychloroquine) and modest doses of steroids
resulted in normalization of both patients’ platelet
counts. After discontinuation of supplemental vitamin D
in one patient, the 25-OH vitamin D normalized, but the
platelet count subsequently plummeted. Resuming vita-
min D supplementation restored the platelet count to
the previous normal range. We postulate that vitamin D
may work synergistically with Plaquenil
W (hydroxy
chloroquine) through unknown mechanisms; we have
found the combined regimen works better than vitamin
D alone. This treatment option may also down-regulate
the proliferation of CD4+ cells and up-regulate T regula-
tory cells. These combined effects may potentially
reduce the autoantibody response.
The successful treatment of ITP can be variable, and
the toxicity of many of the existing treatments is consider-
able. The discovery and development of efficacious and
non-toxic treatment for ITP is therefore imperative.
Plaquenil
W (hydroxychloroquine) has been used clinically
for over 50 years and has an exceptional safety record. It is
probably the safest among the disease-modifying agents
that rheumatologists prescribe. Retinopathy is extremely
rare, and the few reported cases were in patients taking
the drug for more than 5 years. Baseline and annual eye
exams are recommended [25]. Other less common side
effects include rash, tinnitus and muscle aches. It should
not be prescribed to patients with glucose-6-phosphate
dehydrogenase deficiency.
The Case 1 patient was treated with prednisone in
addition to vitamin D when platelet counts dropped subse-
quent to temporary vitamin D discontinuation. Although it
is possible prednisone was responsible for the platelet count
recovery at 3 months post-clinic admission, we feel it is un-
likely for two reasons. First of all, the platelet count signifi-
cantly decreased within one month of discontinuation of
vitamin D. The dosage of prednisone remained unchanged
during this period. Secondly, the patient’s platelet counts
remained stable for 3 months without any prednisone treat-
ment. We recommend that vitamin D levels be obtained on
all patients who are thrombocytopenic; the high prevalence
of vitamin D deficiency in the United States of America
makes this particularly crucial. If vitamin D levels are
less than 30ng/mL, we recommend the patient receive
aggressive replacement with vitamin D supplementation
at high doses.
In our experience the therapeutic dose varies between
50,000 and 100,000IU/week depending on the platelet
count. This dose should be maintained for many months
if the renal function remains normal. When the platelet
count stabilizes, in some patients, vitamin D supplemen-
tation may need to be maintained indefinitely. We also
suggest the addition of Plaquenil
W (hydroxychloroquine)
200mg twice a day, especially if the patient is ANA posi-
tive and/or there is a clinical suggestion of Sjögren’s syn-
drome or SLE. We believe there is a synergistic effect of
Plaquenil
W (hydroxychloroquine) and high-dose vitamin
D that is clinically important and thus recommend
further studies be done to confirm our findings and
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worthy that neither patient experienced any untoward
side effect from high-dose vitamin D, suggesting it is a
safe alternative treatment to a life-threatening condition.
Consent
Written informed consent was obtained from the patients
for publication of this manuscript and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare no competing interests.
Authors’ contributions
BB is the patients’ physician. TBK aided in forming the discussion and
conclusions. BB and TBK wrote the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
We thank Dr Mindy Miner who provided editing services.
Author details
1Arthritis Northwest, 16122 8th Ave SW, Seattle, WA 98166, USA.
2Department of Medicine, University of Washington School of Medicine,
1959 N.E. Pacific Street, Seattle, WA 98195, USA.
3Department of Medicine,
Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street,
Boston, MA 02115, USA.
Received: 5 October 2012 Accepted: 28 February 2013
Published: 4 April 2013
References
1. Fogarty PF: Chronic immune thrombocytopenia in adults: epidemiology
and clinical presentation. Hematol Oncol Clin North Am 2009,
23(6):1213–1221.
2. Thota S, Kistangari G, Daw H, Spiro T: Immune thrombocytopenia in
adults: an update. Cleve Clin J Med 2012, 79(9):641–650.
3. Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BMR, Bussel JB: A
dose of 75mu g/kg/d of i.v. anti-D increases the platelet count more
rapidly and for a longer period of time than 50mu g/kg/d in adults with
immune thrombocytopenic purpura. Br J Haematol 2001, 112(4):1076–1078.
4. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser
GA, Lim W, Kelton JG: Systematic review: efficacy and safety of rituximab
for adults with idiopathic thrombocytopenic purpura. Ann Intern Med
2007, 146(1):25–33.
5. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB: Multiagent induction
and maintenance therapy for patients with refractory immune
thrombocytopenic purpura (ITP). Blood 2007, 110(10):3526–3531.
6. Nandakumar A, Davis S, Moolgavkar S, Witherspoon RP, Schwartz SM:
Myeloid leukaemia following therapy for a first primary cancer.
Br J Cancer 1991, 63(5):782–788.
7. Cines DB, Blanchette VS: Immune thrombocytopenic purpura. N Engl J
Med 2002, 346(13):995–1008.
8. Bromberg ME: Immune thrombocytopenic purpura–the changing
therapeutic landscape. N Engl J Med 2006, 355(16):1643–1645.
9. Kojouri K, Vesely SK, Terrell DR, George JN: Splenectomy for adult patients
with idiopathic thrombocytopenic purpura: a systematic review to
assess long-term platelet count responses, prediction of response, and
surgical complications. Blood 2004, 104(9):2623–2634.
10. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A: Morbidity and
mortality in adults with idiopathic thrombocytopenic purpura. Blood
2001, 97(9):2549–2554.
11. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J: Suppression of in vitro
megakaryocyte production by antiplatelet autoantibodies from adult
patients with chronic ITP. Blood 2004, 103(4):1364–1369.
12. Khan M, Mikhael J: A review of immune thrombocytopenic purpura: focus
on the novel thrombopoietin agonists. J Blood Med 2010, 1:21–31.
13. Muller K, Diamant M, Bendtzen K: Inhibition of production and function of
interleukin-6 by 1,25-dihydroxyvitamin D3. Immunol Lett 1991,
28(2):115–120.
14. Dong X, Bachman LA, Kumar R, Griffin MD: Generation of antigen-specific,
interleukin-10-producing T-cells using dendritic cell stimulation and
steroid hormone conditioning. Transpl Immunol 2003, 11(3–4):323–333.
15. Veldman CM, Cantorna MT, DeLuca HF: Expression of 1,25-
dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem
Biophys 2000, 374(2):334–338.
16. Andersson J: Cytokines in idiopathic thrombocytopenic purpura (ITP).
Acta Paediatr Suppl 1998, 424:61–64.
17. Semple JW, Freedman J: Increased antiplatelet T helper lymphocyte
reactivity in patients with autoimmune thrombocytopenia. Blood 1991,
78(10):2619–2625.
18. Cantorna MT, Hayes CE, DeLuca HF: 1,25-Dihydroxyvitamin D3 reversibly
blocks the progression of relapsing encephalomyelitis, a model of
multiple sclerosis. Proc Natl Acad Sci U S A 1996, 93(15):7861–7864.
19. Pedersen LB, Nashold FE, Spach KM, Hayes CE: 1,25-dihydroxyvitamin D3
reverses experimental autoimmune encephalomyelitis by inhibiting
chemokine synthesis and monocyte trafficking. J Neurosci Res 2007,
85(11):2480–2490.
20. Cantorna MT, Woodward WD, Hayes CE, DeLuca HF: 1,25-dihydroxyvitamin
D3 is a positive regulator for the two anti-encephalitogenic cytokines
TGF-beta 1 and IL-4. J Immunol 1998, 160(11):5314–5319.
21. Shevach EM: Regulatory/suppressor T cells in health and disease. Arthritis
Rheum 2004, 50(9):2721–2724.
22. Pyzik M, Piccirillo CA: The TGF-beta1/Foxp3 regulatory axis in immune
self-tolerance: implications for health and disease. Inflamm Allergy Drug
Targets 2006, 5(3):167–177.
23. Tran DQ, Ramsey H, Shevach EM: Induction of FOXP3 expression in naive
human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming
growth factor-beta dependent but does not confer a regulatory
phenotype. Blood 2007, 110(8):2983–2990.
24. Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO: Induction of
Treg by monocyte-derived DC modulated by vitamin D3 or
dexamethasone: differential role for PD-L1. Eur J Immunol 2009,
39(11):3147–3159.
25. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF, American
Academy of Ophthalmology: Recommendations on screening for
chloroquine and hydroxychloroquine retinopathy: a report by the
American Academy of Ophthalmology. Ophthalmology 2002,
109(7):1377–1382.
doi:10.1186/1752-1947-7-91
Cite this article as: Bockow and Kaplan: Refractory immune
thrombocytopenia successfully treated with high-dose vitamin D
supplementation and hydroxychloroquine: two case reports. Journal of
Medical Case Reports 2013 7:91.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bockow and Kaplan Journal of Medical Case Reports 2013, 7:91 Page 5 of 5
http://www.jmedicalcasereports.com/content/7/1/91